|
Name |
Myrothecine H
|
| Molecular Formula | C29H36O9 | |
| IUPAC Name* |
(1R,2S,3R,6Z,10S,14E,19R,23S,24R,26R,29R)-10-acetyl-1,29-dihydroxy-2-methyl-22-methylidene-4,11,17,25-tetraoxahexacyclo[21.3.1.13,26.110,14.02,19.019,24]nonacosa-6,14-diene-5,16-dione
|
|
| SMILES |
CC(=O)[C@]12CC/C=C\C(=O)O[C@@H]3C[C@@H]4[C@@]5([C@]3([C@]6(CCC(=C)[C@H](C5)[C@H]6O4)COC(=O)/C=C(/[C@H]1O)\CCO2)C)O
|
|
| InChI |
InChI=1S/C29H36O9/c1-16-7-10-27-15-35-23(32)12-18-8-11-36-28(17(2)30,24(18)33)9-5-4-6-22(31)37-20-13-21-29(34,26(20,27)3)14-19(16)25(27)38-21/h4,6,12,19-21,24-25,33-34H,1,5,7-11,13-15H2,2-3H3/b6-4-,18-12+/t19-,20+,21+,24+,25+,26+,27+,28+,29-/m0/s1
|
|
| InChIKey |
VMSOOBKRIXKGTO-ROKWFXBWSA-N
|
|
| Synonyms |
Myrothecine H
|
|
| CAS | NA | |
| PubChem CID | 156582483 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 528.6 | ALogp: | 1.2 |
| HBD: | 2 | HBA: | 9 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 129.0 | Aromatic Rings: | 7 |
| Heavy Atoms: | 38 | QED Weighted: | 0.39 |
| Caco-2 Permeability: | -5.323 | MDCK Permeability: | 0.00001070 |
| Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.016 |
| Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.42 |
| 30% Bioavailability (F30%): | 0.563 |
| Blood-Brain-Barrier Penetration (BBB): | 0.677 | Plasma Protein Binding (PPB): | 54.60% |
| Volume Distribution (VD): | 0.918 | Fu: | 46.14% |
| CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.488 |
| CYP2C19-inhibitor: | 0.033 | CYP2C19-substrate: | 0.421 |
| CYP2C9-inhibitor: | 0.019 | CYP2C9-substrate: | 0.049 |
| CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.07 |
| CYP3A4-inhibitor: | 0.688 | CYP3A4-substrate: | 0.689 |
| Clearance (CL): | 6.403 | Half-life (T1/2): | 0.787 |
| hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.302 |
| Drug-inuced Liver Injury (DILI): | 0.724 | AMES Toxicity: | 0.4 |
| Rat Oral Acute Toxicity: | 0.664 | Maximum Recommended Daily Dose: | 0.939 |
| Skin Sensitization: | 0.066 | Carcinogencity: | 0.815 |
| Eye Corrosion: | 0.358 | Eye Irritation: | 0.061 |
| Respiratory Toxicity: | 0.029 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004393 | ![]() |
0.812 | D06XHC | ![]() |
0.264 | ||
| ENC004254 | ![]() |
0.783 | D0M2QH | ![]() |
0.259 | ||
| ENC004446 | ![]() |
0.683 | D0Q4SD | ![]() |
0.258 | ||
| ENC002026 | ![]() |
0.629 | D0P0HT | ![]() |
0.254 | ||
| ENC003310 | ![]() |
0.472 | D0EP0C | ![]() |
0.247 | ||
| ENC003943 | ![]() |
0.417 | D0IX6I | ![]() |
0.246 | ||
| ENC002240 | ![]() |
0.397 | D06AEO | ![]() |
0.246 | ||
| ENC004775 | ![]() |
0.395 | D0KR5B | ![]() |
0.246 | ||
| ENC003126 | ![]() |
0.393 | D0AR3J | ![]() |
0.246 | ||
| ENC004774 | ![]() |
0.392 | D02JNM | ![]() |
0.245 | ||